Regeneron Pharmaceuticals has had a turbulent season with its share value outperforming competitors on several strong trading days. Its spac owner
Leonard S. Schleifer sold substantial company shares, leading some to scrutinize the firm's
financial health. Meanwhile, they secured a temporary restraining order preventing the
generic launch of Eylea and reported better-than-feared Eylea sales. Despite this, certain reports suggest concern over overpricing and underperformance. The company announced collaboration on gene editing therapies with
Doudna-founded Mammoth causing further scrutiny from investors. Amid these investigations, the Department of Justice levelled a complaint against
Regeneron related to drug-price manipulation hindered the company's stock performance. Despite a weak start, Regeneron's share price surged after the DOJ complaint, hitting a record high amidst new wins. NOTWITHSTANDING this tumult,
Regeneron continues to grow and outperform competitors, with the exceptions, such as when the FDA rejected a lymphoma candidate. The firm rallied despite an earnings miss, capitalizing on pipeline prospects.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Sun, 19 May 2024 14:46:21 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -2
